Your browser doesn't support javascript.
loading
Post COVID 19 acute acalculous cholecystitis raising the possibility of underlying dysregulated immune response, a case report.
Alhassan, Shahda Mohamed; Iqbal, Phool; Fikrey, Lubna; Mohamed Ibrahim, Mohanad Ibrahim; Qamar, Muhammad Sohaib; Chaponda, Masautso; Munir, Waqar.
Afiliação
  • Alhassan SM; Hamad Medical Corporation, Doha, Qatar.
  • Iqbal P; Hamad Medical Corporation, Doha, Qatar.
  • Fikrey L; Hamad Medical Corporation, Doha, Qatar.
  • Mohamed Ibrahim MI; Hamad Medical Corporation, Doha, Qatar.
  • Qamar MS; Ozarks Medical Center, Missouri, USA.
  • Chaponda M; Hamad Medical Corporation, Doha, Qatar.
  • Munir W; Communicable Disease Center, Doha, Qatar.
Ann Med Surg (Lond) ; 60: 434-437, 2020 Dec.
Article em En | MEDLINE | ID: mdl-33224493
ABSTRACT

INTRODUCTION:

Novel Coronavirus disease 2019 or COVID-19 has rapidly spread throughout the world and has become an unprecedented pandemic. It has a vast spectrum of clinical presentations and can affect various organs. Rarely, it has been reported to cause acalculous cholecystitis in a non ICU setting patient. CASE PRESENTATION Here we report a rare association of COVID 19 with acalculous cholecystitis in a 40 years old healthy woman. She developed fever, malaise, generalized body weakness, and right hypochondrial pain after fourteen days of COVID 19 infection, raising the possibility of Post COVID dysregulated immune response resulting in acalculous cholecystitis. She was managed conservatively with broad spectrum antibiotics.

DISCUSSION:

Acalculous cholecystitis primarily occurs due to the gall bladder's hypomotility and most commonly seen in critically ill patients such as severe burns, mechanically ventilated patients, and prolonged parenteral nutrition. The management depends upon treating the underlying pathology and, in some severe cases, may need surgical intervention as well. Up to our knowledge, COVID 19, causing acalculous cholecystitis, is a rare association described only in a few critically ill patients but not in young, healthy patients. It can be attributed to the body's dysregulated immunological response against the virus resulting in systemic inflammation.

CONCLUSION:

Currently, there is are no clear guidelines for managing acute cholecystitis in COVID-19 patients. It depends on the patient's clinical state and disease severity. We aim to highlight the importance of early diagnosis and management in such clinical scenarios to avoid fatal complications.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Qualitative_research / Screening_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Qualitative_research / Screening_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article